CS08399 for MTAP-Deleted Tumors and Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This early-stage trial tests a new drug called CS08399 in people with advanced or hard-to-treat cancers (solid tumors or lymphoma) that have a specific genetic change called MTAP deletion. The drug may help slow or stop cancer growth in people whose cancers no longer respond to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a confirmed MTAP or CDKN2A deletion (a specific genetic change) found in a tissue or blood test
- Your cancer must be advanced, metastatic (spread), relapsed, or refractory (didn't respond to standard treatment) with no other standard options available
- You must have at least one measurable tumor lesion visible on imaging
- You must be 18 years or older and able to swallow pills by mouth
- You must be in reasonably good health (KPS score ≥60 for brain tumors, ECOG 0-1 for other cancers) with life expectancy of at least 3 months
- You cannot have received cancer treatment or experimental drugs within 28 days before starting, and must have recovered from side effects of prior treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HSK41959 combined with standard cancer treatment for people with solid tumors that lack a gene called MTAP. It may help if your tumor has this specific genetic change.
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.